Becn2 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
[^1]
[^2]
[^3]
[^4]
[^5]
[^6]
[^7]
| BECN2 Protein |
|---|
| Protein Name | Beclin-2 |
| Gene | [BECN2](/genes/becn2) |
| UniProt ID | Q9U6C4 |
| Molecular Weight | 46.2 kDa |
| Subcellular Localization | Golgi apparatus, Endosomes, Cytoplasm |
| Protein Family | Beclin family, PI3K complex |
| Chromosomal Location | 5q13.2 |
| Associated Diseases | Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, ALS, Obesity, Cancer |
BECN2 (Beclin-2) is a key regulator of autophagy that interacts with class I PI3K signaling pathways. It plays critical roles in both macroautophagy and selective autophagy, particularly targeting misfolded proteins and protein aggregates. BECN2 serves as a molecular bridge between nutrient sensing, growth factor signaling, and the autophagy machinery.
| Domain |
Position |
Function |
| BH3 domain |
1-30 |
Pro-apoptotic, binds Bcl-2 |
| CCD (Coiled-Coil Domain) |
112-243 |
Dimerization, protein interactions |
| ECD (Evolutionarily Conserved Domain) |
244-450 |
PI3K complex binding, membrane association |
| LIR (LC3-Interacting Region) |
269-280 |
Autophagosome recruitment |
BECN2 exhibits tissue-specific expression:
- Brain: High expression in cortex, hippocampus, basal ganglia, and cerebellum
- Neurons: Particularly abundant in pyramidal neurons and Purkinje cells
- Glia: Moderate expression in astrocytes and microglia
- Peripheral: Heart, liver, skeletal muscle with lower levels
- Development: Increased expression during synaptic plasticity periods
BECN2 forms part of the PI3K complex (VPS34/VPS15/BECN2) that generates PI3P on isolation membranes, a critical step in autophagosome nucleation.
- Aggregate clearance: Recruits ubiquitinated protein aggregates to autophagosomes
- Organelle quality control: Mitophagy, reticulophagy
- Pathogen clearance: Xenophagy of intracellular pathogens
- mTORC1 coordination: Integrates growth factor and nutrient signals
- AMPK response: Energy stress activates BECN2-mediated autophagy
- Receptor tyrosine kinase signaling: Modulates EGFR and insulin receptor trafficking
BECN2 assembles the class III PI3K complex:
| Component |
Function |
| VPS34 (PIK3C3) |
Lipid kinase, generates PI3P |
| VPS15 (PIK3R4) |
Regulatory subunit, kinase activity |
| BECN2 |
Scaffold, substrate recruitment |
| ATG14L |
Targeting to autophagosomes |
- Initiation: BECN2-PI3P complex nucleates phagophore
- Expansion: LC3-II recruited via LIR domain
- Closure: Autophagosome membrane fusion
- Fusion: Lysosomal fusion via SNARE proteins
| Partner |
Interaction Type |
Functional Outcome |
| BCL2/BCL-XL |
BH3 domain binding |
Inhibits autophagy |
| VPS34 |
CCD domain |
PI3K complex |
| LC3/GABARAP |
LIR motif |
Autophagosome targeting |
| p62/SQSTM1 |
Co-operation |
Selective autophagy |
| OPTN |
Co-operation |
Ubiquitin selective autophagy |
- Amyloid clearance: BECN2-mediated autophagy clears Aβ aggregates
- Tau pathology: Impaired autophagy contributes to tau accumulation
- Synaptic dysfunction: Autophagic-lysosomal pathway disruption in AD
- Neuronal vulnerability: BECN2 reduction in AD brain
- α-Synuclein clearance: BECN2-dependent mitophagy clears damaged mitochondria
- Mitochondrial quality control: PINK1/Parkin-BECN2 axis
- Lewy body formation: Impaired autophagic clearance
- Dopaminergic neuron survival: BECN2 protection in PD models
- Mutant huntingtin clearance: Autophagy induction via BECN2
- Aggregate removal: Reduction of mHTT aggregates
- Neuronal protection: BECN2 overexpression improves phenotype
- Protein aggregate clearance: TDP-43, SOD1 aggregate removal
- Axonal transport: Autophagosome-lysosome trafficking
- Motor neuron survival: BECN2 protective in mouse models
| Compound |
Mechanism |
Stage |
| Rapamycin |
mTOR inhibition |
Preclinical |
| Metformin |
AMPK activation |
Clinical trials |
| Carbamazepine |
Beclin-1 cleavage |
Preclinical |
| Vitamin D |
BECN2 upregulation |
Observational |
- AAV-BECN2: Viral delivery of BECN2
- BECN2 activators: Small molecule allosteric modulators
- miRNA targeting: Anti-miR therapy to upregulate BECN2
- Autophagy + proteasome: Dual-target approaches
- BECN2 + TFEB: Coordinated upregulation
- Anti-aggregation + clearance: Comprehensive therapy
- BECN2 expression: Peripheral blood mononuclear cells
- Autophagy flux: LC3-II/LC3-I ratio
- p62 levels: Autophagy substrate clearance
- Becn2⁻/⁻ mice: Embryonic lethal (different from Becn1)
- Conditional knockout: Neurodegeneration phenotype
- Tissue-specific deletion: Neuronal loss, aggregate formation
- BECN2 overexpression: Neuroprotection in AD/PD models
- Humanized BECN2: Studying human-specific functions
- Mutant BECN2: Disease-associated variants
- BECN2 haploinsufficiency enhances neurodegeneration
- Autophagy induction protects against protein aggregates
- BECN2-PI3K complex is druggable target
- How does BECN2 specificity arise for different cargo?
- What determines neuronal vulnerability to BECN2 loss?
- Can BECN2 activation be achieved safely in humans?
- Single-cell proteomics: BECN2 heterogeneity in neurons
- CRISPR screens: Genetic modifiers of BECN2 function
- Structural biology: BECN2-PI3K complex cryo-EM
The study of Becn2 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.